Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Knee Osteoarthritis
- Sponsor
- Labrha
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Number of adverse event attributable to the investigational Medical Device during the week following each injection.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies.
The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly.
The present clinical investigation has the objective to evaluate the safety of use of Pandora in a single injection or in three injections performed weekly.
Detailed Description
This clinical investigation is a multicenter, prospective, open study of a class III Medical Device. This study is designed to evaluate the safety of use of Pandora in its two forms : in a single injection or in three injections. A descriptive analysis will be carried out to characterize the demographic data, the history of the disease and its treatments, the clinical and radiological data of the patients at inclusion. The security of use of Pandora will be demonstrated by describing the proportion of patients with at least one adverse event attributable to the treatment, occurring during the week following each injection. In total, 20 participants will be enrolled across two study centers in France, 10 participants in each centers. The total duration of subjects participation is 6 months ; overall study duration including the enrollment period is expected to take approximately 9 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient aged between 35 and 85 years.
- •Body mass index (BMI) \< 30 kg.m\^
- •Medial or lateral femoro-tibial knee osteoarthritis, diagnosed according to the American College of Rheumatology criteria, radiological stage 2 and 3 according to the Kellgren-Lawrence criteria modified by Felson on an X-ray, of the knee in extension, less than 12 months old.
- •Knee osteoarthritis responsible for walking pain in the target knee, assessed between 4 and 8 inclusive on an 11 points numerical scale (0 = none to 10 = extreme).
- •Ambulatory patient able to walk 50 meters without a cane, crutch or walker.
- •Patient able to read, understand, sign and date the patient information sheet.
- •Patient agreeing to follow-up study visits.
- •Patient affiliated to the health social security system.
- •Patient requiring viscosupplementation according to the investigator.
Exclusion Criteria
- •Patient presenting knee osteoarthritis without impingement joint space narrowing of the femoro-tibial compartment (modified Kellgren stage 0-1) or with complete impingement joint space narrowing on the knee weight-bearing radiograph in extension (modified Kellgren stage 4).
- •Walking pain in the target knee, rated less than 4 or more than 8 on an 11-point numerical scale (0 = none to 10 = extreme).
- •Patient with a flare of osteoarthritis of the target or contralateral knee attested by KOFUS criteria ≥
- •Patient who received viscosupplementation or Platelet Rich Plasma (PRP) injection in the 6 months prior to inclusion.
- •Patient who received an intra-articular injection of corticosteroids in the target knee in the 2 months prior to inclusion.
- •Patients with a skin condition or a wound next to or near the injection site.
- •Patients refusing to discontinue treatment with NSAIDs or cox-2 inhibitors during the follow-up period.
- •Patient receiving treatment with level III analgesics (strong opioids).
- •Patients receiving treatment with diacerhein, avocado and soy unsaponifiables, glucosamine or chondroitin initiated less than 2 months prior to inclusion.
- •Patient with hypersensitivity to hyaluronic acid or tranexamic acid.
Outcomes
Primary Outcomes
Number of adverse event attributable to the investigational Medical Device during the week following each injection.
Time Frame: 1 month
Adverse events will be collected at : * Day 8 for Happyone arm (single injection) ; * Days 8, 15 and 22 for Happysoft arm (three injections).
Secondary Outcomes
- Number of adverse events during the month following the first injection for immediate and delayed local tolerance evaluation.(1 month)
- Patient self-assesment of the overall tolerance of the treatment based on a 5-point scale, from "Very bad" to "Very good".(1 month)
- Variation over time of the WOMAC score, between time of injection and end point, and the WOMAC subscores A (pain) and C (function). The WOMAC-Questionnaire is based on a 11 points scale, from 0 = None to 10 = Extreme.(6 months)
- Patient self-assesment of the effectiveness of the treatment based on a 11 points numeric scale, from 0 = None to 10 = Total.(6 months)